Literature DB >> 19926553

White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system.

.   

Abstract

OBJECTIVE: To convene a group of expert stakeholders to develop recommendations for standardizing systems for the implementation of risk evaluation and mitigation strategies (REMS). DATA SOURCES: On July 15, 2009, the American Pharmacists Association convened an expert panel of stakeholders to explore standardized solutions to REMS development and implementation. Meeting participants included pharmacists from various practice settings, physicians, researchers, patient advocates, and a nursing delegate, and the meeting was observed by a U.S. Food and Drug Administration representative. The stakeholders' recommendations were combined with themes arising from discussion of their experiences with existing REMS, and a review of the literature on REMS and risk management was performed by the author.
SUMMARY: A systematic, standardized REMS process that balances the need to control the risks of medications with the need to minimize the impact on patient access is required. A standardized REMS system could address various aspects of development and implementation, including the creation of specific REMS "levels," centralized systems for data management and program structure, public education, individualized patient education, provider education, access to medications, pilot testing, outcomes monitoring, and quality of care.
CONCLUSION: Several strategies to streamline the development and implementation of a REMS system are feasible. Incorporating such strategies is necessary to manage the rapidly growing number of individual and diverse REMS programs that patients and health care providers must navigate. Furthermore, a standardized REMS system could be used to improve quality of care and support patient education and empowerment.

Entities:  

Mesh:

Year:  2009        PMID: 19926553     DOI: 10.1331/JAPhA.2009.09541

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  6 in total

Review 1.  Postmarketing surveillance for "modified-risk" tobacco products.

Authors:  Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2011-01-20       Impact factor: 4.244

2.  Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Authors:  Inge M Zomerdijk; Fakhredin A Sayed-Tabatabaei; Gianluca Trifirò; Stella C F Blackburn; Miriam C J M Sturkenboom; Sabine M J M Straus
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

3.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

4.  A comparison of patients' and pharmacists' satisfaction with medication counseling provided by community pharmacies: a cross-sectional survey.

Authors:  Seungwon Yang; Dasohm Kim; Hye Joung Choi; Min Jung Chang
Journal:  BMC Health Serv Res       Date:  2016-04-14       Impact factor: 2.655

5.  The Journey of the American Society for Pain Management Nursing Into Advocacy and Governmental Affairs.

Authors:  Wade Delk; Ann Quinlan-Colwell
Journal:  Pain Manag Nurs       Date:  2020-08-20       Impact factor: 1.929

6.  Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids.

Authors:  Gregory D Salinas; Caroline O Robinson; Maziar Abdolrasulnia
Journal:  J Pain Res       Date:  2012-10-05       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.